External Validation of a Clinical Scoring System for Hematuria

  • Lee, Seung Bae (Department of Urology, Seoul National University Boramae Hospital) ;
  • Kim, Hyung Suk (Department of Urology, Seoul National University Hospital) ;
  • Kim, Myong (Department of Urology, Seoul National University Hospital) ;
  • Ku, Ja Hyeon (Department of Urology, Seoul National University Hospital)
  • 발행 : 2014.08.30


Background: The aim of this study was to evaluate the accuracy of a new scoring system in Korean patients with hematuria at high risk of bladder cancer. Materials and Methods: A total of 319 consecutive patients presenting with painless hematuria without a history of bladder cancer were analyzed, from the period of August 2012 to February 2014. All patients underwent clinical examination, and 22 patients with incomplete data were excluded from the final validation data set. The scoring system included four clinical parameters: age (${\geq}50$ = 2 vs. <50 =1), gender (male = 2 vs. female = 1), history of smoking (smoker/ex-smoker = 4 vs. non-smoker = 2) and nature of the hematuria (gross = 6 vs. microscopic = 2). Results: The area under the receiver-operating characteristic curve (95% confidence interval) of the scoring system was 0.718 (0.655-0.777). The calibration plot demonstrated a slight underestimation of bladder cancer probability, but the model had reasonable calibration. Decision curve analysis revealed that the use of model was associated with net benefit gains over the treat-all strategy. The scoring system performed well across a wide range of threshold probabilities (15%-45%). Conclusions: The scoring system developed is a highly accurate predictive tool for patients with hematuria. Although further improvements are needed, utilization of this system may assist primary care physicians and other healthcare practitioners in determining a patient's risk of bladder cancer.


Hematuria;bladder cancer;scoring system;risk stratification;validation


  1. Alishahi S, Byrne D, Goodman CM, Baxby K (2002). AUDIT SECTION-Haematuria investigations based on a standard protocol: Emphasis on the diagnosis of urological malignancy. J Roy Coll Sug Edin, 47, 422-7.
  2. Botteman MF, Pashos CL, Redaelli A, Laskin B, Hauser R (2003). The health economics of bladder cancer: a comprehensive review of the published literature. Pharmacoeconomics, 21, 1315-30.
  3. Cha EK, Tirsar L-A, Schwentner C, et al (2012a). Immunocytology is a strong predictor of bladder cancer presence in patients with painless hematuria: a multicentre study. Eur Urol, 61, 185-92.
  4. Cha EK, Tirsar L-A, Schwentner C, et al (2012b). Accurate risk assessment of patients with asymptomatic hematuria for the presence of bladder cancer. World J Urol, 30, 847-52.
  5. Chuttiangtum A, Udomthavornsuk B, Chumworathayi B (2012) Hematuria screening test for urinary bladder mucosal infiltration in cervical cancer. Asian Pac J Cancer Prev, 13, 4931-33
  6. Cohen RA, Brown RS (2003). Microscopic hematuria. New England J Med, 348, 2330-8.
  7. Davis R, Jones JS, Barocas DA, et al (2012). Diagnosis, evaluation and follow-up of asymptomatic microhematuria (AMH) in adults: AUA guideline. J Urol, 188, 2473-81.
  8. Gore JL, Lai J, Setodji CM, Litwin MS, Saigal CS (2009). Mortality increases when radical cystectomy is delayed more than 12 weeks. Cancer, 115, 988-96.
  9. Grossfeld GD, Litwin MS, Wolf JS, et al (2001). Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology. Urology, 57, 599-603.
  10. Khadra MH, Pickard RS, Charlton M, Powell PH, Neal DE (2000). A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol, 163, 524-7.
  11. Lotan Y, Capitanio U, Shariat SF, Hutterer GC, Karakiewicz PI (2009). Impact of clinical factors, including a point of care nuclear matrix protein 22 assay and cytology, on bladder cancer detection. BJU Int, 103, 1368-74.
  12. Madeb R, Messing EM (2008). Long-term outcome of home dipstick testing for hematuria. World J Urol, 26, 19-24.
  13. Mariani A, Mariani M, Macchioni C, et al (1989). The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol, 141, 350-5.
  14. Messing E, Young T, Hunt V, Emoto SE, Wehbie JM (1987). The significance of asymptomatic microhematuria in men 50 or more years old: findings of a home screening study using urinary dipsticks. J Urol, 137, 919-22.
  15. Nielsen ME, Shariat SF, Karakiewicz PI, et al (2007). Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol, 51, 699-708.
  16. Shariat SF, Sfakianos JP, Droller MJ, et al (2010). The effect of age and gender on bladder cancer: a critical review of the literature. BJU Int, 105, 300-8.
  17. Shariat SF, Walz J, Roehrborn CG, et al (2008). External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol, 26, 1526-31.
  18. Siegel R, DeSantis C, Virgo K, et al (2012). Cancer treatment and survivorship statistics, 2012. CA-Cancer J Clin, 62, 220-41.
  19. Sutton JM (1990). Evaluation of hematuria in adults. JAMA, 263, 2475-80.
  20. Tan GH, Shah SA, Ann HS, et al (2013). Stratifying patients with haematuria into high or low risk groups for bladder cancer: a novel clinical scoring system. Asian Pac J Cancer Prev, 14, 6327-30.
  21. Van Der Aa MN, Steyerberg EW, Sen EF, et al (2008). Patients' perceived burden of cystoscopic and urinary surveillance of bladder cancer: a randomized comparison. BJU Int, 101, 1106-10.
  22. Vickers AJ, Elkin EB (2006). Decision curve analysis: a novel method for evaluating prediction models. Med Decis Making, 26, 565-74.
  23. Yavuzcan A, Caglar M, Kayikci MA, et al (2013) Can reproductive characteristics predict bladder cancer in women with haematuria? Asian Pac J Cancer Prev, 14, 5107-10.